Navigation Links
Fate Therapeutics announces creation of small molecule platform for commercial-scale reprogramming
Date:10/18/2009

La Jolla, CA October 18, 2009 Fate Therapeutics, Inc. announced today the generation of human induced-pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming. The discoveries, which were made by Sheng Ding, Ph.D. under a research collaboration between Fate Therapeutics and The Scripps Research Institute (TSRI), represent a more than 200-fold improvement in reprogramming efficiency and reduce the reprogramming period to two weeks as compared to methods using only the four reprogramming factors (Oct 3/4, Sox2, Klf4 and c-Myc). This latest advancement has broad implications for the creation of "pharmaceutical grade" iPSCs, reprogrammed cells that can be produced without genetic modification at commercial scale quantity, quality and consistency and continues to bolster the leadership position of Fate Therapeutics in industrialized iPSC technology. The Company is developing minimally invasive techniques for reprogramming and differentiation and has exclusively in-licensed from TSRI and the Whitehead Institute for Biomedical Research a intellectual property portfolio related to iPSC technology dating back to November 2003.

"While recent studies have reported improved methods of reprogramming, those techniques have relied on further genetic manipulation or have not otherwise addressed a fundamental reprogramming challenge that iPSC generation is still a very slow and inefficient process and results in a heterogeneous population of cells," said Paul Grayson, president & CEO of Fate Therapeutics. "Once again, Dr. Ding and his team are the first group to clear yet another major hurdle required for the widespread commercial use of iPSCs for drug discovery and patient therapies."

The findings of Dr. Ding and his colleagues are published today in the Advanced Online edition of the scientific journal Nature Methods. As compared to using the four reprogram
'/>"/>

Contact: Cory Tromblee
ctromblee@macbiocom.com
617-571-7220
MacDougall Biomedical Communications, Inc.
Source:Eurekalert

Page: 1 2

Related biology news :

1. AACR, NCI and EORTC to host molecular targets and cancer therapeutics conference
2. Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
3. Amarna Therapeutics B.V. and TNO announce SVac research and development partnership
4. Continuous glucose monitoring technology -- special issue of Diabetes Technology and Therapeutics
5. NIH announces new program to develop therapeutics for rare and neglected diseases
6. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
7. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
8. Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
9. A novel target for therapeutics against Staph infection
10. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
11. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Yale University researchers have identified a handful of bacterial ... as Crohn,s disease and ulcerative colitis, using patients, own ... are published Aug. 28 in the journal Cell ... intestinal microbiota, which plays a critical role in the ... only a small number of bacterial species affect a ...
(Date:8/28/2014)... researcher and his collaborators have developed an online analytic ... of re-engineering cells for biomedical investigation. CellNet is a ... aid stem cell engineering. Details of CellNet and its ... back-to-back papers in the journal Cell . , ... for all types of cell-based investigations and can potentially ...
(Date:8/28/2014)...  Privacy Advocate and Senior Staff Attorney at the ... the lineup of biometric and mobile commerce experts set ... Summit in Tampa, Florida on ... include Steven Rahman, Director, Technology and Strategy at Samsung, and ... theme of this year,s event is Mobility at the ...
Breaking Biology News(10 mins):Yale study identifies possible bacterial drivers of IBD 2New tool aids stem cell engineering for medical research 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2
... in the form of reduced snowfall in mountains is ... communities through the increased ability of elk to stay at ... groundbreaking study in Nature Climate Change . , ... only showed that the abundance of deciduous trees and their ...
... children delivered by cesarean section have an increased risk of ... Cohort Study (MoBa) suggests that children delivered by cesarean section ... three. This was particularly seen among children without a hereditary ... than 37 000 participants in the MoBa study were used ...
... frequently caused by smoking and exposure to carcinogens in the ... of cancer in men,and women in the U.S. More than ... or less and have not invaded the muscle layer. At ... the burning away of tumors with high energy electricity (fulguration). ...
Cached Biology News:Dramatic links found between climate change, elk, plants, and birds 2Tapping the body's own defenses, researchers look to cutting-edge gene therapy for bladder cancer 2
(Date:8/29/2014)... 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... results for the six months ended June 30, ... Canadian dollars and presented under International Financial Reporting ... , Announced top-line results related to ... for subjects enrolled in the Phase 2 iDEAL ...
(Date:8/29/2014)... MA, San Antonio, TX (PRWEB) August 29, 2014 ... ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 ... has been awarded an international Phase II clinical ... with non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic ... including, but not limited to, protocol and charter ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
(Date:8/28/2014)... , Aug. 28, 2014   SunTrust Robinson ... three industry veterans to its equity research team ... "Our ongoing expansion in equity research demonstrates our ... unique insights to enhance their investment decision making," ... at STRH.  "We continue to make significant investments ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... Oct. 4 Auxogyn, Inc., a privately held medical ... that it acquired an exclusive license from Stanford University ... medical practitioners in the field of assisted reproduction to ... fertilization (IVF) procedures. The technology licensed from ...
... CryoLife, Inc. (NYSE: CRY ), an implantable ... today that it has appointed David P. Lang as ...  In this newly created position, Mr. Lang will have ... distribution strategies for PerClot, a novel hemostatic agent that ...
... (SIX: RO, ROG; OTCQX: RHHBY) announced today that the cobas ... 201 system is now available with the CE Mark. It ... human genotypes of parvovirus B19 (B19V) and hepatitis A virus (HAV) ... amplification technology (NAT) test which simultaneously quantifies B19V genotypes 1, 2 ...
Cached Biology Technology:Auxogyn Licenses Non-invasive Embryo Assessment Technology From Stanford University 2David P. Lang Appointed Vice President of CryoLife International, Inc. 2David P. Lang Appointed Vice President of CryoLife International, Inc. 3David P. Lang Appointed Vice President of CryoLife International, Inc. 4First Duplex Test for Parvovirus B19 and Hepatitis A Virus Increases Safety of Human Plasma and Plasma Products 2First Duplex Test for Parvovirus B19 and Hepatitis A Virus Increases Safety of Human Plasma and Plasma Products 3
...
... requiring mass detection but not structural ... Mass spectrometer is ideally suited for ... high performance mass analysis. Typical ... protein detection, micro-satellite DNA characterization and ...
Rat Aortic Smooth Muscle Cells (RAOSMC) (>500,000 cells)...
Rat Dermal Fibroblasts (RDF) (>500,000 cells)...
Biology Products: